<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1990</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОТ РЕДАКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FROM EDITOR</subject></subj-group></article-categories><title-group><article-title>Интервью в рамках цикла «Мнение лидеров»</article-title><trans-title-group xml:lang="en"><trans-title>Interview as Part of the "Leadership Opinion" Series</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редакционная</surname><given-names>статья</given-names></name><name name-style="western" xml:lang="en"><surname>Editorial</surname><given-names>Article</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2024</year></pub-date><volume>13</volume><issue>4</issue><fpage>13</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Редакционная с., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Редакционная с.</copyright-holder><copyright-holder xml:lang="en">Editorial a.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1990">https://www.pharmjournal.ru/jour/article/view/1990</self-uri><abstract><p>Представляем вашему вниманию новое интервью в рамках цикла «Мнение лидеров». Сегодняшним гостем стала вице-президент по развитию бизнеса ГК «Фармасинтез» Наталья Малых. В роли интервьюера выступила Кульджанова Наталья Вячеславовна, директор научно-производственного журнала «Разработка и регистрация лекарственных средств».</p></abstract><trans-abstract xml:lang="en"><p>We present to your attention a new interview as part of the Leaders' Opinion series. Today’s guest is Natalya Malykh, Vice President for Business Development at Pharmasyntez Group of Companies. The interviewer was Natalya V. Kuldzhanova, director of the scientific and production journal "Drug development and registration".</p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
